UF Records Analysis Links Glucosamine to 25% Higher Dementia Conversion in MCI Patients

The team applied machine learning to deidentified UF Health records spanning 2012-2024, identifying 1,896 ADRD and 2,750 MCI patients who reported glucosamine use. After adjusting for age, sex, and demographics, glucosamine correlated with accelerated conversion from MCI to dementia and a 25% rise in mortality among those already diagnosed with ADRD. Spatial metabolomics on brain tissue and mouse models implicated excess protein O-GlcNAcylation as the candidate pathway disrupted by the supplement.

Glucosamine, a hexosamine that crosses the blood-brain barrier, feeds directly into the hexosamine biosynthetic pathway already upregulated in Alzheimer’s. This metabolic overlap explains why the association appeared stage-specific: MCI patients showed faster progression while those with established dementia showed higher mortality, consistent with cumulative metabolic load rather than acute toxicity.

No randomized trial yet exists, and observational confounding by joint-pain severity or polypharmacy cannot be excluded. Confirmation requires a prospective RCT stratifying MCI patients by glucosamine exposure and tracking conversion rates over 24 months using CDR-SB and PET biomarkers.